Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
Marked interindividual variability in voriconazole exposure persists among CYP2C19 NMs and IMs. Integrating therapeutic drug monitoring (TDM) with genetic and clinical factors may optimize dosing and reduce hepatotoxicity risk. Larger multicentre studies are still needed.
Authors
- Aiqin Li
- Xiaoshuang He
- Jie Fang
- Beiming Xu
- Hui Li
- Qiuya Lu
- Xiaolan Bian
Institutions
- Ruijin Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1093/jac/dkag065
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00